Hunan Warrant Pharmaceutical Co (SHSE:688799) EBIT: ¥232 Mil (TTM As of Mar. 2026)


SHSE:688799 Hunan Warrant Pharmaceutical Co Ltd SHSE:688799
83 GF Score
Price ¥43.38
GF Value ¥33.09
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hunan Warrant Pharmaceutical Co EBIT?

Hunan Warrant Pharmaceutical Co SHSE:688799 -4.68% 83 EBIT is ¥232 Mil as of Mar. 2026. GuruFocus rates SHSE:688799 with a GF Score™ of 83/100 and a GF Value™ of ¥33.09 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Hunan Warrant Pharmaceutical Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥34 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥232 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hunan Warrant Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 was 4.42%. Hunan Warrant Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hunan Warrant Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.71%.


Hunan Warrant Pharmaceutical Co  (SHSE:688799) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hunan Warrant Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=143.016 * ( 1 - 19.02% )/( (2515.512 + 2729.544)/ 2 )
=115.8143568/2622.528
=4.42 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3053.643 - 324.353 - ( 213.778 - max(0, 410.703 - 1176.225+213.778))
=2515.512

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3240.175 - 302.371 - ( 208.26 - max(0, 391.169 - 1106.688+208.26))
=2729.544

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Hunan Warrant Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=137.42/( ( (1002.677 + max(480.181, 0)) + (1176.506 + max(443.227, 0)) )/ 2 )
=137.42/( ( 1482.858 + 1619.733 )/ 2 )
=137.42/1551.2955
=8.86 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(210.377 + 392.46 + 287.676) - (324.353 + 0 + 85.979)
=480.181

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(175.122 + 390.97 + 267.782) - (302.371 + 0 + 88.276)
=443.227

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hunan Warrant Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=231.995/6261.437
=3.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Warrant Pharmaceutical Co EBIT Related Terms


Hunan Warrant Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Hunan Warrant Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Warrant Pharmaceutical Co EBIT Chart

Hunan Warrant Pharmaceutical Co Annual Data
Trend Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 180.76 187.26 230.38 161.69 241.54

Hunan Warrant Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.90 31.60 50.72 115.32 34.36

SHSE:688799 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Warrant Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Warrant Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Warrant Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hunan Warrant Pharmaceutical Co's EV-to-EBIT falls into.


SHSE:688799
83GF Score
Hunan Warrant Pharmaceutical Co Ltd SHSE:688799
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hunan Warrant Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥232 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥232 Mil mean?
Hunan Warrant Pharmaceutical Co (SHSE:688799) has a EBIT of ¥232 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hunan Warrant Pharmaceutical Co.
Is Hunan Warrant Pharmaceutical Co's EBIT too high?
Hunan Warrant Pharmaceutical Co's current EBIT is ¥232 Mil. Overall, Hunan Warrant Pharmaceutical Co has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Warrant Pharmaceutical Co's EBIT compare to ZTS?
Hunan Warrant Pharmaceutical Co's EBIT of ¥232 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hunan Warrant Pharmaceutical Co. Hunan Warrant Pharmaceutical Co's current EBIT is ¥232 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Warrant Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co (SHSE:688799) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥33.09, compared to a current price of ¥43.38 — trading 31.1% above its estimated fair value. The current EBIT is ¥232 Mil. Hunan Warrant Pharmaceutical Co's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hunan Warrant Pharmaceutical Co (SHSE:688799), the current EBIT is ¥232 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hunan Warrant Pharmaceutical Co (SHSE:688799) Overvalued in 2026?

Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥43.38 is trading 31.1% above its estimated GF Value™ of ¥33.09. GuruFocus considers Hunan Warrant Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:688799:

  • EBIT: ¥232 Mil
  • GF Value™: ¥33.09 vs. price of ¥43.38 (31.1% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the SHSE:688799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hunan Warrant Pharmaceutical Co Business Description

Address No. 28 Lutian Road, Building C6-C7, Yuelu District, Changsha, CHN, 410006
Hunan Warrant Pharmaceutical Co Ltd is a pharmaceutical manufacturer. It is engaged in the research and development, production and sales of chemical raw materials, chemical medicine preparations and Chinese medicine preparations.
83GF Score

Get the complete analysis for SHSE:688799

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥43.38
Price
¥33.09
GF Value